Induction Chemotherapy for p16 Positive Oropharyngeal Squamous Cell Carcinoma.

Abstract

Objectives/HypothesisWe aimed to determine the effectiveness of induction chemotherapy for treating p16‐positive oropharyngeal cancer in our department.Study DesignThis was a retrospective case series to assess treatment effectiveness.MethodsWe administered induction chemotherapy to patients with stage III to IV oropharyngeal p16‐positive squamous cell carcinoma between 2008 and 2013. Induction chemotherapy was administered using combinations of docetaxel, cisplatin, and 5‐fluorouracil. We measured the survival rates using the Kaplan‐Meier method and log‐rank test.ResultsWe reviewed 23 patients (18 men and 5 women; age, 42–79 years). Induction chemotherapy resulted in partial or complete remission (20 patients) and in stable (2 patients) or progressive (1 patient) disease. In partial or complete remission, subsequent radiotherapy was performed in 16 patients, chemoradiotherapy in two, and transoral resection in two. In stable or progressive disease, subsequent open surgery was performed. Overall, one patient died of cervical lymph node metastasis, one died of kidney cancer, and one died of myocardial infarction. Event‐free, distant‐metastasis–free survival was present for 20 patients. The 3‐year disease‐specific survival was 95%; the overall survival was 87%. Two patients required gastrostomies during chemoradiotherapy and three required tracheotomies, but these were closed in all patients.ConclusionThe therapeutic response to induction chemotherapy for p16‐positive oropharyngeal cancer was good. Partial or complete remission was achieved in almost 90% patients, and control of local and distant metastases was possible when it was followed by radiotherapy alone or with transoral resection of the primary tumor. A multicenter study is required to confirm these findings.Level of Evidence4.